Oxford Biomedica (OXB) Competitors GBX 613.10 +17.10 (+2.87%) As of 10/3/2025 12:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock OXB vs. ABC, GNS, ONT, ERGO, SLN, PRTC, HZD, VRP, FARN, and AVCTShould you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Abcam (ABC), Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry. Oxford Biomedica vs. Its Competitors Abcam Genus Oxford Nanopore Technologies Ergomed Silence Therapeutics PureTech Health Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Faron Pharmaceuticals Oy Avacta Group Abcam (LON:ABC) and Oxford Biomedica (LON:OXB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership. Does the media refer more to ABC or OXB? In the previous week, Abcam's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score. Company Overall Sentiment Abcam Neutral Oxford Biomedica Neutral Is ABC or OXB more profitable? Abcam has a net margin of 0.00% compared to Oxford Biomedica's net margin of -145.98%. Abcam's return on equity of 0.00% beat Oxford Biomedica's return on equity.Company Net Margins Return on Equity Return on Assets AbcamN/A N/A N/A Oxford Biomedica -145.98%-202.50%-12.67% Which has preferable earnings & valuation, ABC or OXB? Abcam has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbcam£350.40M0.00N/A£0.06N/AOxford Biomedica£151.21M4.87-£143.51M-£0.42-1,468.51 Do analysts prefer ABC or OXB? Oxford Biomedica has a consensus target price of GBX 593.67, suggesting a potential downside of 3.17%. Given Abcam's higher possible upside, research analysts plainly believe Abcam is more favorable than Oxford Biomedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abcam 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders & institutionals have more ownership in ABC or OXB? 32.4% of Oxford Biomedica shares are held by institutional investors. 43.3% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAbcam beats Oxford Biomedica on 7 of the 11 factors compared between the two stocks. Get Oxford Biomedica News Delivered to You Automatically Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OXB vs. The Competition Export to ExcelMetricOxford BiomedicaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£736.83M£234.58M£6.08B£2.61BDividend Yield4.57%3.80%5.68%5.31%P/E Ratio-1,468.5131.1978.055,440.99Price / Sales4.876,041.57577.14262,752.65Price / Cash3.0113.1937.7927.90Price / Book9.06107.2612.558.04Net Income-£143.51M-£90.99M£3.31B£5.89B7 Day Performance12.23%4.46%4.28%4.35%1 Month Performance5.74%7.91%7.85%6.56%1 Year Performance59.25%600.27%71.37%140.53% Oxford Biomedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OXBOxford Biomedica0.9142 of 5 starsGBX 613.10+2.9%GBX 593.67-3.2%+61.3%£736.83M£151.21M-1,468.51891Gap UpABCAbcamN/AN/AN/AN/A£2.81B£350.40M20,433.331,650Gap UpHigh Trading VolumeGNSGenus2.1021 of 5 starsGBX 2,344.02-1.1%GBX 2,900+23.7%+22.8%£1.54B£672.80M-37,806.69480ONTOxford Nanopore Technologies2.6584 of 5 starsGBX 156.10-0.4%GBX 245+57.0%+1.8%£1.50B£204.69M-1,054.731,281ERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health2.5678 of 5 starsGBX 127.86+2.0%GBX 455+255.8%-2.7%£309.03M£6.17M752.14300Positive NewsHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpFARNFaron Pharmaceuticals OyN/AGBX 192+1.1%N/A-14.6%£214.95MN/A-711.1134News CoverageAVCTAvacta Group2.1171 of 5 starsGBX 52.71+1.4%N/A+39.8%£211.77M£113K-343.61120News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Abcam Alternatives Genus Alternatives Oxford Nanopore Technologies Alternatives Ergomed Alternatives Silence Therapeutics Alternatives PureTech Health Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Faron Pharmaceuticals Oy Alternatives Avacta Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:OXB) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
